PP_1170x120_10-25-21

US WorldMeds

US WorldMeds, Adamis Pharmaceuticals announce U.S. launch of ZIMHI Naloxone Product

US WorldMeds, Adamis Pharmaceuticals announce U.S. launch of ZIMHI Naloxone Product

LOUISVILLE, Ky. — USWM (US WorldMeds), and Adamis Pharmaceuticals Corporation,  today announced the U.S. launch and availability of ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present. According to the Centers

US WorldMeds and Salix announce U.S. roll out of Lucemyra

US WorldMeds and Salix announce U.S. roll out of Lucemyra

LOUISVILLE, K.Y. and BIDGEWATER, N.J. – US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc., today announced the U.S. launch and availability of Lucemyra (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The Centers

FDA approves US WorldMeds’ Lucemyra for opioid withdrawal symptoms

FDA approves US WorldMeds’ Lucemyra for opioid withdrawal symptoms

LOUISVILLE, Ky. — US WorldMeds  announced that the U.S. Food and Drug Administration (FDA) approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The FDA reviewed Lucemyra under Priority Review, which is granted to submissions for medications that would provide significant improvements in the safety or effectiveness of